恩威医药
(301331)
| 流通市值：8.52亿 | | | 总市值：26.47亿 |
| 流通股本：3310.17万 | | | 总股本：1.03亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 373,545,589.69 | 370,274,493.59 | 366,010,905.68 | 453,622,367.33 |
| 应收票据及应收账款 | 129,280,731.92 | 120,242,245.29 | 104,098,324.83 | 115,623,174.07 |
| 应收账款 | 129,280,731.92 | 120,242,245.29 | 104,098,324.83 | 115,623,174.07 |
| 应收款项融资 | 139,748,154.81 | 176,286,463.6 | 122,812,093.88 | 98,773,030.37 |
| 预付款项 | 27,913,185.73 | 21,123,606.07 | 25,311,174.63 | 14,112,034.68 |
| 其他应收款合计 | 5,038,456.66 | 3,690,219.26 | 5,652,462.64 | 4,695,988.32 |
| 存货 | 116,623,924.61 | 115,551,553.67 | 107,488,765.03 | 127,727,285.78 |
| 其他流动资产 | 103,592.13 | 145,216.1 | 3,518,333.58 | 1,804,484.9 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 942,025,659.66 | 952,037,157.23 | 864,538,310.27 | 916,330,278.24 |
| 非流动资产: | | | | |
| 长期股权投资 | 374,400.42 | 374,400.42 | 330,447.34 | 380,006.03 |
| 投资性房地产 | 27,876,934.55 | 28,476,170.6 | 29,075,406.65 | 29,674,642.7 |
| 固定资产 | 197,379,787.12 | 203,115,833.3 | 209,539,965.27 | 210,943,934.92 |
| 在建工程 | 52,821,102.15 | 40,367,890.07 | 35,605,470.48 | 21,291,143.43 |
| 使用权资产 | 2,752,398.74 | 3,067,597.55 | 2,112,921.03 | 1,660,093.84 |
| 无形资产 | 129,350,945.22 | 133,373,685.11 | 137,396,425.04 | 139,987,487.54 |
| 商誉 | 100,552,610.87 | 100,552,610.87 | 100,552,610.87 | 100,552,610.87 |
| 长期待摊费用 | 8,653,984.89 | 8,695,004.89 | 7,311,330.6 | 8,659,188.84 |
| 递延所得税资产 | 4,675,323.45 | 4,640,491.01 | 6,483,749.38 | 5,661,498.53 |
| 其他非流动资产 | 29,806,977 | 29,828,077 | 29,947,914.8 | 36,185,037.8 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 554,244,464.41 | 552,491,760.82 | 558,356,241.46 | 554,995,644.5 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 1,496,270,124.07 | 1,504,528,918.05 | 1,422,894,551.73 | 1,471,325,922.74 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 47,766,193.03 | 49,493,170.61 | 30,387,324.73 | 44,640,038.51 |
| 应付账款 | 47,766,193.03 | 49,493,170.61 | 30,387,324.73 | 44,640,038.51 |
| 合同负债 | 27,328,267.8 | 24,611,986.13 | 17,670,831.76 | 19,942,022.17 |
| 应付职工薪酬 | 28,917,336.83 | 34,089,766.95 | 30,305,022.79 | 32,609,290.05 |
| 应交税费 | 10,773,514.56 | 15,237,905.61 | 11,844,093.36 | 14,396,435.37 |
| 其他应付款合计 | 82,819,898.46 | 100,428,951.66 | 84,175,658.86 | 99,347,070.3 |
| 一年内到期的非流动负债 | 11,374,118.03 | 11,360,809.26 | 1,344,118.8 | 1,298,079.24 |
| 其他流动负债 | 3,552,674.81 | 3,199,558.19 | 2,297,208.13 | 2,592,462.87 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 212,532,003.52 | 238,422,148.41 | 178,024,258.43 | 214,825,398.51 |
| 非流动负债: | | | | |
| 长期借款 | 185,000,000 | 185,000,000 | 200,000,000 | 220,000,000 |
| 租赁负债 | 1,376,324.97 | 1,520,766.19 | 617,197.82 | - |
| 递延收益 | 9,378,601.41 | 9,957,429.51 | 10,211,263.25 | 10,779,186.08 |
| 递延所得税负债 | 11,478,225.6 | 11,957,490.45 | 12,077,693.94 | 12,160,760.83 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 207,233,151.98 | 208,435,686.15 | 222,906,155.01 | 242,939,946.91 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 419,765,155.5 | 446,857,834.56 | 400,930,413.44 | 457,765,345.42 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 102,891,887 | 102,891,887 | 102,891,887 | 102,891,887 |
| 资本公积 | 641,239,733.69 | 638,710,975.5 | 661,056,632.87 | 654,540,897.79 |
| 减:库存股 | 59,176,866.88 | 59,176,866.88 | 101,753,887.68 | 99,554,193.72 |
| 盈余公积 | 36,909,308.03 | 36,909,308.03 | 35,069,179.5 | 35,069,179.5 |
| 未分配利润 | 354,640,906.73 | 338,335,779.84 | 324,700,326.6 | 320,612,806.75 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 1,076,504,968.57 | 1,057,671,083.49 | 1,021,964,138.29 | 1,013,560,577.32 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 1,076,504,968.57 | 1,057,671,083.49 | 1,021,964,138.29 | 1,013,560,577.32 |
| 负债和股东权益合计 | 1,496,270,124.07 | 1,504,528,918.05 | 1,422,894,551.73 | 1,471,325,922.74 |
| 公告日期 | 2025-04-21 | 2025-04-21 | 2024-10-24 | 2024-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |